Zeo ScientifiX, Inc. (ZEOX)

Market Cap	13.68M -28.4%
Revenue (ttm)	5.56M +21.9%
Net Income	-5.13M
EPS	-0.78
Shares Out	7.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,428
Average Volume	6,352
Open	1.950
Previous Close	2.000
Day's Range	1.650 - 1.950
52-Week Range	1.200 - 3.320
Beta	3.92
RSI	39.22
Earnings Date	Jun 12, 2026

About Zeo ScientifiX

Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarthritis,and traumatic brain injury. The company also provides Patient Pure X, an autologous biologic, that helps reduce inflammation and promote tissue h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 20
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZEOX

Financial Performance

In fiscal year 2025, Zeo ScientifiX's revenue was $5.20 million, an increase of 12.53% compared to the previous year's $4.62 million. Losses were -$5.52 million, 17.3% more than in 2024.